The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial-Mesenchymal Transition

It would be highly desirable to find prognostic and predictive markers for triple-negative breast cancer (TNBC), a strongly heterogeneous and invasive breast cancer subtype often characterized by a high recurrence rate and a poor outcome. Here, we investigated the prognostic and predictive capabilit...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 24; no. 7; p. 6422
Main Authors Zapperi, Stefano, La Porta, Caterina A M
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 29.03.2023
MDPI
Subjects
Adjuvant treatment
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast cancer
Cancer
Cancer therapies
Chemotherapy
Classification
Clinical trials
Comparative analysis
Disease-Free Survival
drug response
Epithelial-Mesenchymal Transition - genetics
epithelial–mesenchymal transition
Gene expression
Gene Expression Profiling
Humans
Immunotherapy
Lymphatic system
Machine learning
Medical prognosis
Metastasis
Neoadjuvant Therapy - methods
Patients
Statistical analysis
Stem cells
Surgery
Transcriptomics
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - genetics
triple-negative breast cancer
Tumors
drug response
epithelial–mesenchymal transition
triple-negative breast cancer
Online AccessGet full text

Cover

More Information
Summary:It would be highly desirable to find prognostic and predictive markers for triple-negative breast cancer (TNBC), a strongly heterogeneous and invasive breast cancer subtype often characterized by a high recurrence rate and a poor outcome. Here, we investigated the prognostic and predictive capabilities of ARIADNE, a recently developed transcriptomic test focusing on the epithelial-mesenchymal transition. We first compared the stratification of TNBC patients obtained by ARIADNE with that based on other common pathological indicators, such as grade, stage and nodal status, and found that ARIADNE was more effective than the other methods in dividing patients into groups with different disease-free survival statistics. Next, we considered the response to neoadjuvant chemotherapy and found that the classification provided by ARIADNE led to statistically significant differences in the rates of pathological complete response within the groups.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24076422